PMID- 35213378
OWN - NLM
STAT- MEDLINE
DCOM- 20220413
LR  - 20220716
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Print)
IS  - 1387-2877 (Linking)
VI  - 86
IP  - 3
DP  - 2022
TI  - Serum Amyloidogenic Nanoplaques and Cytokines in Alzheimer's Disease: Pilot Study 
      in a Small Naturalistic Memory Clinic Cohort.
PG  - 1459-1470
LID - 10.3233/JAD-215504 [doi]
AB  - BACKGROUND: Neuroinflammation is a central component of Alzheimer's disease (AD) 
      and correlates closely with amyloid pathology. Markers of inflammation such as 
      cytokines, and amyloidogenic aggregates, so-called nanoplaques, are both 
      promising biomarker candidates for AD. We have previously shown that there is a 
      relationship between the levels of nanoplaques and cytokines in cerebrospinal 
      fluid, but it is unknown whether this association extends to serum. OBJECTIVE: 
      Investigate in a naturalistic memory clinic cohort whether the associations 
      between nanoplaques and cytokines in the cerebrospinal fluid extends to serum. 
      METHODS: We collected serum from 49 patients assessed for cognitive complaints at 
      the Oslo University Hospital Memory Clinic (15 with clinical AD). We assessed the 
      levels of serum nanoplaques with the novel Thioflavin-T fluorescence correlation 
      spectroscopy (ThT-FCS) assay. Serum levels of nine cytokines (eotaxin-1, 
      granulocyte colony-stimulating factor [G-CSF], interleukin [IL]-6, IL-7, IL-8, 
      monocyte chemoattractant protein-1 (MCP-1), gamma induced protein 10 (IP-10), 
      macrophage inflammatory protein [MIP]-1alpha, and MIP-1beta) were quantified with a 
      multiplex assay and read on a Luminex IS 200 instrument. RESULTS: Serum 
      nanoplaques were not increased in clinical AD patients compared to non-AD memory 
      clinic patients and nanoplaques were not associated with any cytokines. The 
      cytokines IL-8 and G-CSF were increased in patients with clinical AD compared to 
      non-AD patients. CONCLUSION: In this small pilot study, serum nanoplaques were 
      not associated with serum cytokines. Nanoplaque levels could not be used to 
      separate clinical AD patients from non-AD patients in this unselected memory 
      clinic cohort.
FAU - Aksnes, Mari
AU  - Aksnes M
AD  - Department of Geriatric Medicine, Institute of Clinical Medicine, Faculty of 
      Medicine, University of Oslo, Norway.
FAU - Aass, Hans Christian D
AU  - Aass HCD
AD  - Department of Medical Biochemistry, Oslo University Hospital, Norway.
FAU - Tiiman, Ann
AU  - Tiiman A
AD  - Department of Clinical Neurosciences (CNS), Center for Molecular Medicine CMM 
      L8:01, Karolinska Institutet, Stockholm, Sweden.
FAU - Terenius, Lars
AU  - Terenius L
AD  - Department of Clinical Neurosciences (CNS), Center for Molecular Medicine CMM 
      L8:01, Karolinska Institutet, Stockholm, Sweden.
FAU - Bogdanovic, Nenad
AU  - Bogdanovic N
AD  - Department of Geriatric Medicine, Institute of Clinical Medicine, Faculty of 
      Medicine, University of Oslo, Norway.
AD  - Department of Neurobiology, Care Science and Society (NVS), Division of Clinical 
      Geriatrics, Karolinska Institutet, Huddinge, Sweden.
FAU - Vukojevic, Vladana
AU  - Vukojevic V
AD  - Department of Clinical Neurosciences (CNS), Center for Molecular Medicine CMM 
      L8:01, Karolinska Institutet, Stockholm, Sweden.
FAU - Knapskog, Anne-Brita
AU  - Knapskog AB
AD  - Department of Geriatric Medicine, The Memory Clinic, Oslo University Hospital, 
      Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - *Alzheimer Disease/pathology
MH  - Biomarkers/cerebrospinal fluid
MH  - Cytokines
MH  - Granulocyte Colony-Stimulating Factor
MH  - Humans
MH  - Interleukin-6
MH  - Interleukin-8
MH  - Pilot Projects
PMC - PMC9108575
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Thioflavin T
OT  - amyloid
OT  - amyloid-beta peptide
OT  - biomarkers
OT  - cytokines
OT  - fluorescence
OT  - serum
COIS- Authors' disclosures available online 
      (https://www.j-alz.com/manuscript-disclosures/21-5504r1).
EDAT- 2022/02/26 06:00
MHDA- 2022/04/14 06:00
PMCR- 2022/05/16
CRDT- 2022/02/25 17:15
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/04/14 06:00 [medline]
PHST- 2022/02/25 17:15 [entrez]
PHST- 2022/05/16 00:00 [pmc-release]
AID - JAD215504 [pii]
AID - 10.3233/JAD-215504 [doi]
PST - ppublish
SO  - J Alzheimers Dis. 2022;86(3):1459-1470. doi: 10.3233/JAD-215504.